Key Points
- CEO Serge Saxonov sold shares: Saxonov sold 5,000 shares on March 24 at $19.52 for $97,600 and, including prior sales on March 23 and Feb 23, sold a total of 24,632 shares in Feb–Mar for roughly $467,863, reducing his stake by about 0.42% to 1,172,273 shares.
- Stock and results snapshot: TXG trades near $20.91 (market cap ≈ $2.67B) with a 52‑week range of $6.78–$23.56; the company recently beat EPS estimates (‑$0.13 vs. ‑$0.19) on $166.03M revenue, and analysts’ consensus is a "Hold" with an average target of $18.46.
10x Genomics (NASDAQ:TXG - Get Free Report) CEO Serge Saxonov sold 5,000 shares of the company's stock in a transaction on Tuesday, March 24th. The stock was sold at an average price of $19.52, for a total value of $97,600.00. Following the transaction, the chief executive officer directly owned 1,172,273 shares in the company, valued at approximately $22,882,768.96. The trade was a 0.42% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link.
Serge Saxonov also recently made the following trade(s):
- On Monday, March 23rd, Serge Saxonov sold 10,000 shares of 10x Genomics stock. The stock was sold at an average price of $19.13, for a total value of $191,300.00.
- On Monday, February 23rd, Serge Saxonov sold 9,632 shares of 10x Genomics stock. The shares were sold at an average price of $18.58, for a total value of $178,962.56.
10x Genomics Stock Performance
Shares of NASDAQ TXG opened at $20.91 on Thursday. The company has a market cap of $2.67 billion, a PE ratio of -59.74 and a beta of 2.20. The business has a 50-day simple moving average of $20.04 and a two-hundred day simple moving average of $16.86. 10x Genomics has a fifty-two week low of $6.78 and a fifty-two week high of $23.56.
10x Genomics (NASDAQ:TXG - Get Free Report) last issued its quarterly earnings results on Thursday, February 12th. The company reported ($0.13) earnings per share for the quarter, topping analysts' consensus estimates of ($0.19) by $0.06. 10x Genomics had a negative return on equity of 6.89% and a negative net margin of 6.77%.The business had revenue of $166.03 million for the quarter, compared to analyst estimates of $160.35 million. During the same quarter in the previous year, the firm earned ($0.40) earnings per share. The company's revenue was up .6% on a year-over-year basis. On average, sell-side analysts predict that 10x Genomics will post -1.43 earnings per share for the current fiscal year.
Institutional Trading of 10x Genomics
Institutional investors and hedge funds have recently bought and sold shares of the business. Allworth Financial LP boosted its holdings in shares of 10x Genomics by 150.4% in the 2nd quarter. Allworth Financial LP now owns 2,271 shares of the company's stock valued at $26,000 after acquiring an additional 1,364 shares during the last quarter. Geneos Wealth Management Inc. purchased a new position in shares of 10x Genomics during the fourth quarter worth $38,000. Larson Financial Group LLC raised its holdings in shares of 10x Genomics by 164.4% during the fourth quarter. Larson Financial Group LLC now owns 2,364 shares of the company's stock worth $39,000 after purchasing an additional 1,470 shares during the last quarter. True Wealth Design LLC lifted its position in 10x Genomics by 26.4% during the third quarter. True Wealth Design LLC now owns 4,534 shares of the company's stock valued at $53,000 after purchasing an additional 948 shares during the period. Finally, Abich Financial Wealth Management LLC acquired a new position in 10x Genomics during the third quarter valued at $56,000. 84.68% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
A number of research analysts have issued reports on TXG shares. Barclays upped their price target on shares of 10x Genomics from $17.00 to $22.00 and gave the company an "overweight" rating in a research note on Monday, December 15th. Leerink Partners dropped their price objective on shares of 10x Genomics from $22.00 to $20.00 and set a "market perform" rating on the stock in a report on Tuesday, January 27th. UBS Group upped their target price on 10x Genomics from $14.00 to $20.00 and gave the company a "neutral" rating in a research report on Friday, February 20th. Citigroup lowered 10x Genomics from a "buy" rating to a "cautious" rating in a research note on Thursday, December 11th. Finally, Bank of America set a $21.00 price target on 10x Genomics in a research report on Monday, January 12th. Four investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $18.46.
Check Out Our Latest Stock Report on 10x Genomics
About 10x Genomics
(
Get Free Report)
10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.
Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
